The announcement is based on early data from a phase 2a clinical trial that involved 202 non-hospitalized COVID-19 patients. The pill, molnupiravir, was well tolerated by the participants and significantly reduced their viral load.
The drugmakers are continuing to study the drug in phase 2/3 clinical programs, which will test it in both outpatient and hospital settings.
More articles on pharmacy:
Moderna vaccine causing delayed rash in some recipients, small study says
COVID-19 drug doesn’t benefit patients with mild illness, study finds
Drugmakers studying how to administer COVID-19 vaccines without a needle
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
